PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.



 

PMID- 29699474
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20180507
IS  - 2038-2529 (Electronic)
IS  - 0300-8916 (Linking)
VI  - 104
IP  - 1
DP  - 2018 Jan-Feb
TI  - Stable knockdown of ZBTB7A promotes cell proliferation and progression in
      nasopharyngeal carcinoma.
PG  - 37-42
LID - 10.5301/tj.5000706 [doi]
AB  - AIMS: Although high expression of ZBTB7A is positively relative to metastasis in 
      nasopharyngeal carcinoma (NPC) patients, the association between its low
      expression and metastasis of NPC remains unclear. The present study aimed to
      definitely identify the association. METHODS: The level of ZBTB7A was effectively
      knocked down by stable transfection of short hair RNA plasmid in NPC cell lines
      CNE2 and 5-8F (shRNA-CNE2 and shRNA-5-8F), compared with the cells that stably
      transfected empty plasmid (NC-CNE2 and NC-5-8F). The levels of ZBTB7A were
      assessed by real-time polymerase chain reaction and Western blot in the cell
      lines. MTT assay, colorimetric focus-formation assay, flow cytometry, wound
      healing assay, transwell assays, and xenograft model were performed to analyze
      cell vitality, proliferation, cell cycle, migration, invasion, and
      tumorigenicity. RESULTS: The levels of ZBTB7A were effectively reduced in
      shRNA-CNE2 and shRNA-5-8F. Their carcinogenicity was stronger separately than the
      abilities of NC-CNE2 and NC-5-8F. NC-CNE2 and shRNA-CNE2 were selected to
      establish the xenograft model because of their stronger tumorigenicity than
      NC-6-10B and shRNA-5-8F. The assay showed that shRNA-CNE2 had stronger
      tumorigenicity than NC-CNE2. CONCLUSIONS: The results demonstrated the reverse
      association between the expression of ZBTB7A and the tumorigenicity of NPC. We
      postulate that some oncogenic pathways, which are suppressed by ZBTB7A, will
      vicariously promote the proliferation and progression of NPC when ZBTB7A is
      decreased.
FAU - Liu, Fei
AU  - Liu F
AD  - 1 Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang
      Autonomous Region, Nanning, Guangxi - PR China.
FAU - Tang, Fengzhu
AU  - Tang F
AD  - 2 Department of Otorhinolaryngology, The People's Hospital of Guangxi Zhuang
      Autonomous Region, Nanning, Guangxi - PR China.
FAU - Lan, Jiao
AU  - Lan J
AD  - 1 Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang
      Autonomous Region, Nanning, Guangxi - PR China.
FAU - Jiao, Wei
AU  - Jiao W
AD  - 1 Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang
      Autonomous Region, Nanning, Guangxi - PR China.
FAU - Si, Yongfeng
AU  - Si Y
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
FAU - Lu, Wensheng
AU  - Lu W
AD  - 1 Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang
      Autonomous Region, Nanning, Guangxi - PR China.
FAU - Mo, Mingzheng
AU  - Mo M
AD  - 1 Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang
      Autonomous Region, Nanning, Guangxi - PR China.
FAU - Li, Bing
AU  - Li B
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
FAU - Lu, Jinlong
AU  - Lu J
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
FAU - Wei, Jiazhang
AU  - Wei J
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
FAU - Qin, Ying
AU  - Qin Y
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
FAU - Xiao, Ruiping
AU  - Xiao R
AD  - 1 Research Center of Medical Sciences, The People's Hospital of Guangxi Zhuang
      Autonomous Region, Nanning, Guangxi - PR China.
FAU - Zhang, Benjian
AU  - Zhang B
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
FAU - Wang, Yongli
AU  - Wang Y
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
FAU - Xiong, Weiming
AU  - Xiong W
AD  - 3 Department of Otolaryngology-head and Neck Oncology, The People's Hospital of
      Guangxi Zhuang Autonomous Region, Nanning, Guangxi - PR China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumori
JT  - Tumori
JID - 0111356
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (ZBTB7A protein, human)
SB  - IM
MH  - Animals
MH  - Carcinoma/*genetics/pathology/therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*genetics
MH  - Cell Survival/genetics
MH  - DNA-Binding Proteins/*genetics/metabolism
MH  - Disease Progression
MH  - Humans
MH  - Mice, Inbred BALB C
MH  - Nasopharyngeal Neoplasms/*genetics/pathology/therapy
MH  - *RNA Interference
MH  - RNAi Therapeutics/methods
MH  - Transcription Factors/*genetics/metabolism
MH  - Tumor Burden/genetics
MH  - Xenograft Model Antitumor Assays/methods
OTO - NOTNLM
OT  - Invasion
OT  - Migration
OT  - Nasopharyngeal carcinoma
OT  - Proliferation
OT  - Viability
OT  - ZBTB7A
EDAT- 2018/04/28 06:00
MHDA- 2018/05/08 06:00
CRDT- 2018/04/28 06:00
PHST- 2018/04/28 06:00 [entrez]
PHST- 2018/04/28 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
AID - 10.5301/tj.5000706 [doi]
PST - ppublish
SO  - Tumori. 2018 Jan-Feb;104(1):37-42. doi: 10.5301/tj.5000706.